


January 9, 2015

To the Editor:

We guarantee that the language of our manuscript has reached Grade A and therefore we choose not to have it edited by any English language editing company. Likewise, the text has been actively reviewed by the senior author of the paper (Dr. Pedro A. López Saura, MD, PhD), with wide experience in such writings, accepted by several English language journals (the list of such publications in the last 5 years is enclosed). Besides it was reviewed by Dr. Yaima Doimeadiós, PhD, Full Professor of the University of Havana, who is English-certified by Cambridge University (certificate is enclosed).

Yours sincerely



Dr. Francisco Hernández-Bernal

1. Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. *BioMed Central Cancer* 2009; 9:146.
2. Penton-Rol G, Cervantes Llano M, Martínez-Sánchez G, Cabrera-Gomez JA, Valenzuela Silva C, Ramirez-Nunez O, Casanova-Orta M, Robinson-Agramonte MA, Lopategui-Cabezas I, Lopez Saura P. TNF-alpha and IL-10 downregulation and marked oxidative stress in Neuromyelitis Optica. *J Inflamm* 2009;6:18.
3. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. *BioMed Central Cancer* 2009; 9:262
4. Berlanga Acosta J, Schultz GS, Lopez-Saura P. Biology of Diabetic Wound. In: Overhaussen PE, ed. *Foot Ulcers: Causes, Diagnosis and Treatments*, Nova Science Publishers, Inc, 2009.
5. Berlanga-Acosta J, Gavilondo-Cowley J, López-Saura P, González-López T, Castro-Santana MD, López-Mola E, Guillén-Nieto G, Herrera-Martínez L. Epidermal Growth Factor (EGF) in clinical practice- A review of its biological actions, clinical indications and safety implications. *Int Wound J*. 2009; 6(5):331-46.
6. José I Fernández-Montequín JI, Valenzuela-Silva CM, González-Díaz O, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, Sánchez-Penton (MD) P, Morejón-Vega L, Artaza-Sanz H, García-Herrera A, González-Benavides C, Hernández-Cañete CM, Vázquez-Proenza A, Berlanga-Acosta J, López-Saura PA, for the Cuban Diabetic Foot Study Group. Intralesional Injections of Recombinant Human Epidermal Growth Factor Promote Granulation and Healing in Advanced Diabetic Foot Ulcers. Multicenter, Randomized, Placebo-Controlled, Double Blind Study. *Int Wound J*. 2009;6(6):432-43.
7. García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA; FarmaPEG Study Group. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. *BMC Pharmacol*. 2010 Nov 23;10:15.
8. Pentón-Rol G, Martínez-Sánchez G, Cervantes-Llanos M, Lagumersindez-Denis N, Acosta-Medina EF, Falcón-Cama V, Alonso-Ramírez R, Valenzuela-Silva C, Rodríguez-Jiménez E, Llópiz-Arzuaga A, Marín-Prida J, López-Saura PA, Guillén-Nieto GE, Pentón-Arias E. C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells. *Int Immunopharmacol*. 2011; 11(1):29-38.
9. Pentón-Rol G, Marín-Prida J, Pardo-Andreu G, Martínez-Sánchez G, Acosta-Medina EF, Valdivia-Acosta A, Lagumersindez-Denis N, Rodríguez-Jiménez E, Llópiz-Arzuaga A, López-Saura PA, Guillén-Nieto G, Pentón-Arias E. C-Phycocyanin is neuroprotective against global cerebral ischemia/reperfusion injury in gerbils. *Brain Res Bull*. 2011; 86(1-2):42-52.
10. Perea SE, Baladrón I, García Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, García I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoacceptor domain. Translational and clinical research. *Mol Cell Biochem*. 2011; 356(1-2):45-50.

11. Solares AM, Baladron I, Ramos T, Valenzuela C, Borbon Z, Fanjull S, Gonzalez L, Castillo D, Esmir J, Granadillo M, Batte A, Cintado A, Ale M, Fernandez de Cossio ME, Ferrer A, Torrens I, Lopez-Saura P. Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. *ISRN Obstet Gynecol* 2011;2011:292951. Epub 2011 Mar 24.
12. Pimentel González G, García García I, González González J, Pérez Sánchez L, Velasco Mirabal M, Calderón Marín C, García Ruiz FL, García Iglesias E, López de Queralta R, Ropero Toirac R, Ayala Avila M, López Díaz A, López Saura PA, Gavilondo JV, Oliva González JP. Phase I Clinical Trial of the 131I-Labeled anticarcinoembryonic Antigen CIGB-M3 Multivalent Antibody Fragment. *Cancer Biotherapy Radiopharmaceuticals* 2011; 26 (3): 353-363.
13. López-Saura PA, Berlanga-Acosta J, Fernández-Montequín JI, Valenzuela-Silva C, González-Díaz O, Savigne W, Morejon-Vega L, del Río-Martín A, Herrera-Martínez L, López-Mola E, Acevedo-Castro B. Intralesional Human Recombinant Epidermal Growth Factor for the Treatment of Advanced Diabetic Foot Ulcer: From Proof of Concept to Confirmation of the Efficacy and Safety of the Procedure. In *Global Perspective on Diabetic Foot Ulcerations*, Thanh Dinh (Ed.), ISBN: 978-953-307-727-7, InTech, 2011 Available from: <http://www.intechopen.com/articles/show/title/intralesional-human-recombinant-epidermal-growth-factor-for-the-treatment-of-advanced-diabetic-foot>
14. García-García I, Milanés-Virelles MT, López-Saura PA, Suárez-Méndez R, Valdés-Quintana M, Fernández-Olivera N, Valenzuela-Silva CM, González- Méndez L, Santos-Herrera Y, Abreu-Suárez G, Cayón-Escobar I. Adjuvant Interferon Gamma in the Management of Multidrug - Resistant Tuberculosis. In *Understanding Tuberculosis - Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity*, Pere-Joan Cardona (Ed.), ISBN: 978-953-307-942-4, InTech, 2011, Available from: <http://www.intechopen.com/articles/show/title/adjuvant-interferon-gamma-in-the-management-3-of-multidrug-resistant-tuberculosis>.
15. Valenzuela-Silva CM, Tuero-Iglesias AD, García-Iglesias E, González-Díaz O, Del Río-Martín A, Yera Alos IB, Fernández-Montequín JI, López-Saura PA. Granulation Response and Partial Wound Closure Predict Healing in Clinical Trials on Advanced Diabetes Foot Ulcers Treated With Recombinant Human Epidermal Growth Factor. *Diabetes Care*. 2013 Feb;36(2):210-5. doi: 10.2337/dc12-1323. Epub 2012 Sep 10.
16. Berlanga J, Fernández JI, López E, López PA, del Río A, Valenzuela C, Balamero J, Muzio V, Raíces M, Silva R, Acevedo BE, Herrera L. Heberprot-P: A Novel Product for Treating Advanced Diabetic Foot Ulcer. *MEDICC Review*, January 2013, Vol 15, No 1.
17. López-Saura PA, Yera-Alos IB, Valenzuela-Silva C, González-Díaz O, del Río-Martín A, Berlanga-Acosta J, Fernández-Montequín JI, Acevedo-Castro B, López-Mola E, Herrera-Martínez L. Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers. *Adv Pharmacoeconom Drug Safety* 2013; 2: 128. doi:10.4172/2167-1052.1000128.
18. Soriano-García JL, López-Díaz A, Solares-Asteasuainzarra M, Baladrón-Castrillo I, Batista-Albuérne N, García-García I, González-Méndez L, Perera-Negrín Y, Valenzuela-Silva CM, Palau-San Pedro A, Quevedo-Sotolongo LS, Hernández-González I, Silveira-Pablos JM, Chong-López A, Alonso DF, Gómez RE, Renault JY, Perrin P, Sigman H, Gold S, Perea-Rodríguez SE, Acevedo-Castro BE, Herrera-Martínez L, López-Saura PA, for the CERVIFARM-300 Study Group. Pharmacological and Safety Evaluation of CIGB-300, a Casein Kinase 2 Inhibitor Peptide, Administered Intralesionally to Patients with Cervical Cancer Stage IB2/II. *J Cancer Res & Therapy* 2013; in press.
19. Hernández-Bernal F., Valenzuela-Silva C.M., Quintero-Tabío L., Castellanos-Sierra G., Monterrey-Cao D., Aguilera-Barreto A., López-Saura P, for the THERESA-2 Group of Investigators. Recombinant Streptokinase Suppositories in the Treatment of Acute Haemorrhoidal Disease. Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial (THERESA-2). *Colorectal Dis*. 2013 Jun 27. doi: 10.1111/codi.12327. [Epub ahead of print].
20. Yera-Alos I, Alonso-Carbonell L, Valenzuela-Silva CM, Tuero-Iglesias AD, Moreira-Martínez M, Marrero-Rodríguez I, Lopez-Mola E, Lopez-Saura PA. Active Post-Marketing Surveillance of the Intralesional Administration of Human Recombinant Epidermal Growth Factor in Diabetic Foot Ulcers. *BMC Pharmacol Toxicol*. 2013 Sep 3;14(1):44
21. Hernández-Bernal F, Castellanos-Sierra G, Valenzuela-Silva CM, Catasús-Álvarez KM, Valle-Cabrera R, Aguilera-Barreto A, López-Saura PA, for the THERESA-3 (Treatment of HEmorrhoids with REcombinant Streptokinase Application) Group of Investigators. Recombinant Streptokinase versus Phenylephrine-based Suppositories in Acute Hemorrhoids. Randomized, Controlled Trial (THERESA-3). *World J Gastroenterol* 2014; 20(6): 1594-1601.
22. Berlanga-Acosta J, López-Saura P, Guillen-Pérez I, Guillen-Nieto G, Acevedo-Castro B, Herrera-Martínez L. Type 2 Diabetes Mellitus (T2DM): Biological Overview from Pathways to Organelles and its Translation toward a Torpid Wound Healing Process. *J Diabetes Metab* 2013; 4: 7. doi:10.4172/2155-6156.1000285.
23. Bello-Rivero I, Garcia-Vega Y, Valenzuela-Silva C, Bello-Alvarez C, Vázquez-Blomquist D, Lopez-Saura P. Development of a new formulation of interferons (HEBERPAG) for BCC treatment. *J Cancer Res Ther* 2013, 1(10): 235-243.



UNIVERSITY of CAMBRIDGE
Local Examinations Syndicate
INTERNATIONAL EXAMINATIONS

First Certificate in English

This is to certify that
YAIMA DOIMEADIOS REYES

has been awarded
CERTIFICATE GRADE A

in the Examination for the
First Certificate in English

Date of Examination **JUNE 1999**
Place of Entry **HAVANA**
Reference Number **996CU0010012**

Certificate Number 2286223

Vice-Chancellor
University of Cambridge